MedTrace Logo

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-07-29

No results posted yet for this study

Summary

This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.

Conditions

Interventions

DRUG

Liraglutide

Sponsors & Collaborators

  • The Comprehensive NeuroAIDS Center (CNAC) at Temple University

    collaborator UNKNOWN

  • Temple University

    lead OTHER

Principal Investigators

  • Cherie Vaz, MD Dipl ABOM · Temple University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-06-01
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743598 on ClinicalTrials.gov